Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
64Cu-NODAGA-CANF
- Development stage
- Phase 1
- Lead developer
- Washington University School of Medicine
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
64Cu-NODAGA-CANF is a novel positron emission tomography (PET) radiopharmaceutical imaging agent developed by the Washington University School of Medicine. It consists of the positron-emitting radioisotope copper-64 (64Cu) chelated by NODAGA (1,4,7-triazacyclononane-1-glutaric acid-4,7-diacetic acid) and conjugated to C-type atrial natriuretic factor (CANF), a selective peptide ligand for the natriuretic peptide receptor C (NPR-C). NPR-C is upregulated in atherosclerotic plaques, particularly in vulnerable, unstable lesions. 64Cu-NODAGA-CANF is designed for non-invasive PET-MR or PET-CT imaging of carotid atherosclerosis to identify high-risk plaques and predict stroke risk. It is currently being evaluated in Phase 1 clinical trials for dosimetry, safety, and biodistribution in healthy volunteers.
- Other names
- 64Cu-NODAGA-cANF64Cu-NO-cANFcopper-64 NODAGA-CANFcopper64 NODAGA-CANFcopper 64 NODAGA-CANF
02
Targets
NPR3 (Natriuretic peptide receptor C)
Beyond the preview
Go deeper on 64Cu-NODAGA-CANF.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 64Cu-NODAGA-CANF.